Evaluation Viral RNA and Virus Infectivity in Exhaled Air Before and After Use of One Dose With ColdZyme Mouth Spray
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: ColdZyme.
- Who it may be relevant to
- Registry conditions: URTI - Viral Upper Respiratory Tract Infection. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Sweden
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Evaluation of Number of Particles Containing Viral RNA and Their Virus Infectivity in Exhaled Air From Participants With Upper Respiratory Tract Infection Symptoms, Before and After Use of One Dose With ColdZyme Mouth Spray
Overview
Many respiratory diseases spread through aerosols. ColdZyme is a mouth spray that protects against upper respiratory tract viruses causing common cold and flu-like symptoms. ColdZyme forms a protective moisturizing barrier on the mucous membrane of the oral cavity and throat. The objective of this study is assessing if ColdZyme could also contribute to decreased airborne transmission by decreasing the amount of (infectious) virus that is exhaled by an infected subject.
Detailed description
The clinical investigation aims to increase the knowledge about the airborne spread of viruses causing upper respiratory tract infections. In particular, it will investigate whether participants with symptoms of a respiratory infection exhale less viruses causing upper respiratory tract infections after using the ColdZyme mouth spray and if the infectivity of exhaled virus particle is reduced. Data from this clinical investigation can possibly show that ColdZyme mouth spray can help reduce the risk of spreading upper respiratory tract virus to the environment.
This is a single centre open label randomized controlled trial. It is an interventional study where subjects are randomized to treatment group (ColdZyme mouth spray) or control group (no spray). The comparison is made between using a mouth spray and not, which cannot be blinded. There are two primary reasons for single centre. Firstly, this is the first study of treatment effects on exhaled viruses and thus feasibility and sensitivity of the methodology is uncertain. Secondly, only a few laboratories internationally have developed instrumentation to perform the measurements.
Subjects enrolled in the study will participate in two different visits, where only visit 1 is related to this clinical investigation regarding ColdZyme. Visit 2 is only for follow-up and the data collected during this visit is not used for investigation of the primary or secondary endpoints, but for explorative analysis that is not related to the hypothesis for ColdZyme. The reason for the second visit is to compare exhaled aerosol characteristics between healthy subjects and subjects with URTI symptoms.
The first visit takes place when the research subject has symptoms of respiratory illness. During the first visit, exhaled aerosol will be collected pre- and post-treatment for the treatment group, and before and after a waiting time of around 20 minutes for the control group. Lung function tests, nasal swabs and questionnaires will be conducted only once per visit and pre-treatment during the first visit.
The exhaled aerosols will be collected into an aerosol sampler (BioSpot, Aerosol Devices Inc.) and analyzed for virus content via qPCR at a later stage. Virus positive samples will be cultured if possible. The particle size distribution and the concentration of exhaled aerosols will be measured directly at the visit by an optical aerosol instrument (OPC, Grimm Aerosol Technik, GmbH). Basic lung function will be measured during both visits by spirometry, oscillometry and AiDA. Symptom scores are collected during both visits.
All measurements are estimated to be made within 2 hours. During the first visit, when the participants have symptoms of respiratory infection, a second sampling of exhaled aerosol will be initiated 20 minutes after use of the mouth spray, or after a waiting time for the control group. The aerosol sampling takes about 30 minutes.
For assessment of the primary variable for the clinical investigation, i.e. virus presence and concentration in the aerosol samples, polymerase chain reaction (PCR) will be used. Maintenance and calibration of the PCR instrument will be performed routinely at the laboratory, for instance by quality control of PCR data from known standard concentrations. Blank aerosol samples will be collected regularly to ensure that there is no cross-contamination or environmental contamination.
The secondary variable, infectivity of virus in the aerosol samples, will be assessed by infecting cell cultures. Negative control wells with uninfected cells will be present in each cell culture plate to ensure that cells were unaffected by other factors.
Interventions
- Device ColdZyme
ColdZyme is a medical device classified as a Class III device, certified according to the European Medical Devices Regulation (2017/745/EU) (MDR). It has been CE-marked since 2013. ColdZyme is a mouth spray that protects against upper respiratory tract viruses causing common cold and flu-like symptoms. ColdZyme forms a protective moisturizing barrier on the mucous membrane of the oral cavity and throat. The viscous barrier catches the virus and thereby the contact between the virus and the epit
Primary outcome measures
- Number of virus genome copies in exhaled aerosol [Time frame: 20-60 minutes after inhalation of 1 dose treatment of ColdZyme]
Secondary outcome measures (1)
- Infectivity of exhaled virus as quantified by TCID50 and MPN [Time frame: 20-60 minutes after inhalation of 1 dose treatment of ColdZyme]
Eligibility criteria
Inclusion criteria for subject selection:
- Male and female subjects above age 18 (inclusive).
- Presence of self-reported sudden onset of at least one of the following symptoms of upper respiratory tract infection case definitions for ILI and ARI (as defined by ECDC (EU 2008, 2012, 2022): Cough, sore throat, shortness of breath, non-allergic rhinitis, fever or feverishness, malaise, headache, myalgia.
- Otherwise of general good health, according to Investigator's judgement.
- Willing and able to give written informed consent for participation in the investigation.
Exclusion criteria for subject selection.
- Known allergy or hypersensitivity to the components of ColdZyme.
- Current use of immunosuppressive therapy within the last 4 weeks prior to Visit 1 and during the investigation.
- Diagnosed chronic respiratory disease that could potentially impact the investigation results, according to Investigator's judgement.
- Self-reported unhealed wounds/mucosal lesions in the mouth and/or throat.
- Participation in another clinical study or investigation within 30 days prior to Visit 1.
- Active smokers
- The Investigator considers the subject unlikely to comply with investigational procedures, restrictions and requirements.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Prevention
Study locations
Sweden · 1 center
- Lund University — Lund
Publications
- Davison G, Schoeman M, Chidley C, Dulson DK, Schweighofer P, Witting C, Posch W, Matta GG, Consoli C, Farley K, McCullough C, Wilflingseder D. ColdZyme(R) reduces viral load and upper respiratory tract infection duration and protects airway epithelia from infection with human rhinoviruses. J Physiol. 2025 Mar;603(6):1483-1501. doi: 10.1113/JP288136. Epub 2025 Feb 28. PMID 40019230
Identifiers
NCT: NCT07041671 · CIV-24-11-049836